![Astellas Pharma Inc](https://trials-media.s3.amazonaws.com/orgs/astellas-pharma-inc.jpeg)
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal...
CarcinomaRenal Cell2 moreThis is a first in human study of AGS-16M18 given every week to subjects with advanced renal cell cancer. AGS-16M18 will be administered as a 60 minute IV infusion on consecutive days until the disease worsens.
![University of Chicago](https://trials-media.s3.amazonaws.com/orgs/university-of-chicago.jpeg)
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal...
Metastatic Renal Cell CarcinomaThe purpose of this study is to determine whether the experimental vaccine G250 with or without IL-2 can produce an immune response in patients with renal cell carcinoma who have had all their cancer removed by surgery.
![Celgene](https://trials-media.s3.amazonaws.com/orgs/celgene.jpeg)
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients...
Renal Cell CarcinomaThe purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.
![National Cancer Institute (NCI)](https://trials-media.s3.amazonaws.com/orgs/national-cancer-institute-nci.jpeg)
Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small...
Male Breast CancerStage IV Breast Cancer8 moreThis phase I trial is studying the side effects and best dose of cediranib maleate when given together with whole brain radiation therapy in treating patients with brain metastases from non-small cell lung cancer. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays and other types of radiation to kill cancer cells and shrink tumors. Giving cediranib maleate together with radiation therapy may kill more tumor cells
![Assistance Publique - Hôpitaux de Paris](https://trials-media.s3.amazonaws.com/orgs/assistance-publique-hopitaux-de-paris.jpeg)
Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell...
Metastatic Renal Cell CarcinomaThe aim of this study is to identify and/or validate biomarkers and imaging markers to predict and monitor the activity of a new class of therapeutic agents called antiangiogenics for the treatment of metastatic renal cell carcinoma (mRCC). Suntinib, approved for this indication, will be administred before and after nephrectomy and biomarkers sampling and imaging will be operated to monitor the activity and identify prognostic factors in mRCC.
![Dartmouth-Hitchcock Medical Center](https://trials-media.s3.amazonaws.com/orgs/dartmouth-hitchcock-medical-center.jpeg)
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC)...
Metastatic Renal Cell CarcinomaImmune therapies, such as a IL-2, for metastatic renal cell carcinoma (mRCC) are designed to mobilize immune effector cells that recognize and destroy cancer. The investigators have recently observed a 50% objective response rate (16% CR) in mRCC patients treated with autologous tumor lysate -dendritic cell (DC)-vaccine, IL-2 and interferon alfa (IFN). New agents inhibiting vascular endothelial growth factor (VEGF) pathways have demonstrated significant benefit in mRCC patients as well, but rarely induce CRs. High blood VEGF is associated with poor response to IL-2 and can cause tumor specific immune dysregulation. To test whether complementary mechanisms of immune activation and disruption of regulatory pathways enhance outcome the investigators plan to treat 24 mRCC patients in a phase II trial using bevacizumab, DC vaccine, IL-2, and IFN. Observations from this project will be used in the development of novel cancer therapies which, if successful, will decrease the burden of cancer on the public. The investigators propose to determine 1) the objective clinical response rate to treatment and progression free survival, 2) the clinical and autoimmune related toxicity profile of therapy, and 3) the treatment related tumor-specific immune response and the relationship of tumor-specific immune response and objective clinical response.
![Accelerated Community Oncology Research Network](https://trials-media.s3.amazonaws.com/orgs/accelerated-community-oncology-research-network.jpeg)
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal...
Renal Cell CarcinomaThe primary objective of this study is to compare the effectiveness of a dose-escalation regimen (400 to 800mg bid) relative to the standard dosing regimen (400mg bid) of sorafenib given in patients with metastatic RCC. The secondary objectives are to evaluate the effects of the dose-escalation regimen on the quality of life (QoL) of patients with metastatic RCC and to characterize the safety and tolerability profile of a dose-escalation regimen of sorafenib in patients with metastatic RCC.
![National Cancer Institute (NCI)](https://trials-media.s3.amazonaws.com/orgs/national-cancer-institute-nci.jpeg)
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Metastatic MelanomaMetastatic Renal Cell Cancer1 moreBackground: -This study uses an experimental cancer treatment that uses the patient s own lymphocytes (type of white blood cell), which are specially selected and genetically modified to target and destroy their tumor. Objectives: -To test the safety of the treatment and determine if it can cause the patient s tumor to shrink. Eligibility: Patients greater than 18 years and less than or equal to 66 years of age whose cancer has spread beyond the original site and does not respond to standard treatment. Patients have tissue type human leukocyte antigen (HLA)-A*0201. Patients cancer cells have the ESO-1 gene. Design: Workup: Patients have scans, x-rays, laboratory tests, and other tests as needed. Patients have leukapheresis to collect cells for laboratory treatment and later reinfusion. For this procedure, whole blood is collected thorough a tube in a vein, the desired cells are extracted from the blood, and the rest of the blood is returned to the patient. Chemotherapy: Patients have low-dose chemotherapy for 1 week to prepare the immune system to receive the treated lymphocytes. Cell infusion and aldesleukin (IL-2) treatment: Patients receive the lymphocytes by a 30-minute infusion through a vein. Starting within 24 hours of the infusion, they receive high-dose aldesleukin infusions every 8 hours for up to 5 days (maximum15 doses). Recovery: Patients rest for 1 to 2 weeks to recover from the effects of chemotherapy and aldesleukin. Tumor biopsy: Patients may be asked to undergo a biopsy (surgical removal of a small piece of tumor) after treatment to look at the effects of treatment on the immune cells in the tumor. Follow-up: After treatment is completed, patients return to the clinic once a month for several months for physical examinations, a review of side effects, laboratory tests and scans. They may undergo leukapheresis at some visits to look at the effect of treatment on the immune system and check the viability of the infused cells. Patients then return to the National Institute of Health (NIH) clinic once a year for 5 years and then complete a follow-up questionnaire for another 10 years. Retreatment: Patients whose tumor shrinks or disappears following treatment and then recurs may receive one additional treatment, using the same regimen of chemotherapy, lymphocyte infusion and IL-2 treatment.
![M.D. Anderson Cancer Center](https://trials-media.s3.amazonaws.com/orgs/md-anderson-cancer-center.jpeg)
Follow-up After Metastasectomy in Patients With Kidney Cancer
Renal Cell CarcinomaThis phase II trial studies the follow-up after metastasectomy in patients with kidney cancer. Following up patients' health condition after metastasectomy may help doctors to learn if the surgical removal of the primary tumor or the parts of the cancer that has spread to other parts of the body is a good method for treating patients who have kidney cancer.
![Wyeth is now a wholly owned subsidiary of Pfizer](https://trials-media.s3.amazonaws.com/orgs/wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer.jpeg)
A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell...
Renal Cell CarcinomaThis study is being conducted to determine the Maximum Tolerated Dose (MTD) and efficacy of the combined treatment of Temsirolimus and Sunitinib for the treatment of Advanced Kidney Cancer